Congress creates private lawsuits to enforce abortion disclosure rules
H.R. 7237 — Chemical Abortion Risk Awareness Act · Filed by Marlin Stutzman (R-IN) · 2 cosponsors · Introduced Jan 23, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires doctors who perform medication abortions and receive federal funding to provide women with FDA-approved drug labels highlighting warnings and side effects, read those sections aloud, and obtain written confirmation at least 24 hours before the procedure. It allows women to sue providers for violations, claiming actual damages, triple the abortion cost, punitive damages, and attorney fees. The bill defines 'chemical abortion' narrowly to exclude treatment of miscarriage, ectopic pregnancy, and cases where abortion prevents the mother's death or serious bodily harm.
Why we flagged it
The bill's operative mechanism is a mandatory disclosure and informed-consent requirement paired with a private right of action. While framed as 'risk awareness,' the 24-hour waiting period, written confirmation requirement, and triple-damages liability structure function as procedural barriers to abortion access, not merely informational measures.
What the text implies
- The 24-hour waiting period may be unenforceable in states without their own waiting-period laws, creating a patchwork of compliance obligations that varies by state and federal funding source.
- The private right of action creates incentive for litigation against providers even for technical violations (e.g., failure to highlight specific label sections), potentially chilling provision of medication abortion regardless of actual harm.
The full analysis lists 5 implications of this text.
Who stands to gain
plaintiff's attorneys (attorney fee awards); litigation funders targeting abortion providers